2010/06/05

Vaccine hepatitis A

International name:
The vaccine for the prevention of hepatitis A (Vaccine hepatitis A)

Group Affiliation:
MIBP vaccine

Description for commercial items:
AWACS

Mode of action:
Inactivated vaccine for the prevention of viral hepatitis A, containing the hepatitis A virus, inactivated with formaldehyde.

Indications:
Viral hepatitis A (prevention) in adults and children older than 2 years, especially among risk groups: Unvaccinated persons traveling to endemic regions (with a high incidence of hepatitis A), persons exposed to occupational risk of infection (doctors, nursing staff for patients, including care for adults and children, moved to a wheelchair, the staff of sewer and water services, food industry workers and catering), hemophiliacs, patients with multiple blood transfusions, drug addicts who use drugs / c, homosexuals.

Contraindications:
Hypersensitivity (to any component of the vaccine), allergic reactions to previous vaccinations, hyperthermia or acute (or exacerbation of chronic) disease (vaccination is desirable to defer to the normalization condition), pregnancy, laktatsii.C caution. Liver disease, hypersensitivity to neomycin (each dose of vaccine contains trace amounts of neomycin).

Side effects:
Local: pain and hyperemia at the injection site, it is very rare - the seal in the injection site. Common: mild hyperthermia, fatigue, headache, myalgia, arthralgia, and impaired function of the gastrointestinal tract, is rarely - a small reversible increase in activity of "liver" transaminases.

Dosage and administration:
V / m (in the deltoid muscle). Primary vaccination - single 0.5 ml of vaccine. Revaccination - single 0.5 ml after 6-18 months. Subsequent revaccination is recommended that every 10 years.

Cautions:
In / in the introduction is not allowed. When you enter you must make sure that the needle does not penetrate into the blood vessel. To reduce the likelihood of local reactions to the vaccine should enter / m in the deltoid muscle (shoulder muscle). The vaccine should not be used in the gluteal muscles (due to variability in the thickness of the fat layer) or w / c, since in these cases may decrease the immune response. In special cases - patients suffering from thrombocytopenia or bleeding - the vaccine can be administered n / c. The study of this drug during lactation and the effect on embryo or fetus was carried out. However, as for any other inactivated viral vaccines, it seems unlikely that the ability of this drug have side effects on the embryo or fetus. A decision on vaccination of pregnant or lactating women should only be taken on the basis of assessment of real risk of contamination of hepatitis A. Immunosuppressive therapy or immunodeficiency condition can cause a weak immune response to the vaccine. Vaccination is carried out in an incubation period of hepatitis A, may be ineffective. Vaccination with this drug does not prevent viral hepatitis other etiologies, as well as infections caused by other known hepatotropic microorganisms.

Interaction:
The vaccine can be administered simultaneously with Ig under the condition of different parts of the body to inject the vaccine and Ig. Because the vaccine is inactivated, its combination with other inactivated vaccines does not affect the effectiveness of vaccination, provided the introduction of vaccines in different parts of the body (in particular, with recombinant vaccine to prevent hepatitis B, typhoid vaccine, live vaccine for the prevention of yellow fever). The vaccine can be used for revaccination, and in cases where the previous vaccination is carried out other inactivated vaccines for the prevention of hepatitis A.